Dyslipidemia in Indians and South Asians: How it is Different?
21 October 2023
Dyslipidemia in Indians and South Asians: How it is Different?
A combination of hypertriglyceridemia, low levels of HDL-cholesterol and high levels of small dense lowdensity lipoprotein, termed as “atherogenic dyslipidemia’, is particularly seen in Asian Indians.
Indians are prone to develop CHD at a younger age, often before the age of 40 years in men, more likely to have an anterior location of infarction, more likely to have significant left main, multi-vessel, and distal coronary artery disease, similar or lower prevalence of traditional risk factors than with other populations and prevalence of diabetes mellitus is uniformly higher.
Increased abdominal visceral fat and greater insulin resistance at BMI levels that are traditionally considered “ideal” -“thin-fat phenotype”
Although LDL cholesterol comparable to other populations, LDL particle size tends to be smaller.
The serum triglyceride levels are highest in urban Asian Indians residing in India and migrant Asian Indians. Even the average serum triglyceride level of rural-based Asian Indians is higher than Caucasians
Indians not only have lower HDL levels but also have a higher concentration of small, less-protective HDL particles. Indian males have a higher prevalence of low HDL2b , which suggests impaired reverse cholesterol transport
Lipoprotein(a), homocysteine, and plasminogen activator inhibitor-1 levels tend to be higher in South Asians than in white populations
Microalbuminuria is recognized as an independent cardiovascular disease risk factor. Numerous studies have suggested that altered adipokine production or action may play a role in the heightened vascular risk observed in South Asian patients. Altered adipokines may explain why lean nondiabetic Asian Indians have decreased insulin sensitivity compared with others
Fibrates and ω-3 polyunsatalso have antiinflammatory and anti atherogenic properties, and may be additionally useful in Indians who have high prevalence of subclinical inflammation although there is no hard evidence supporting their use